Literature DB >> 6379854

Mechanism of action of cyclosporin A. Effect on T-cell-binding of interleukin 1 and antagonizing effect of insulin.

K Bendtzen, C A Dinarello.   

Abstract

Previous studies have shown that cyclosporin A (CyA) prevents the elaboration of the lymphokine leucocyte migration inhibitory factor (LIF). Since LIF production is interleukin 1 (IL-1)-dependent, we carried out experiments using partially and highly purified IL-1 preparations to study the effect of CyA. We found that (a) IL-1 was consistently depleted during a 1-h incubation with human blood T lymphocytes but not with B lymphocytes or erythrocytes; (b) the depletion could not be ascribed to pinocytosis, cell functions requiring active metabolism, or enzyme-mediated destruction of IL-1; (c) CyA, but not biologically inactive cyclosporin, antagonized the apparent absorption of IL-1; (d) T cells pre-exposed to CyA were rendered incapable of removing the monokine; and (e) CyA was capable of displacing IL-1 once absorbed by T cells. Because the putative binding of IL-1 showed saturability, reversibility (with CyA as a probe), and tissue specificity consistent with a known target for the monokine, we propose that IL-1 interacts with a receptor-like structure on T cells. Finally, we found that insulin interfered with the function of CyA at the very early macrophage-T-cell co-operative stage, even at physiological concentrations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6379854     DOI: 10.1111/j.1365-3083.1984.tb00976.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  2 in total

1.  Inhibitor of interleukin-1 alpha and interleukin-1 beta-induced T-cell activation in serum of patients with active Crohn's disease.

Authors:  J Brynskov; M B Hansen; C Reimert; K Bendtzen
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

2.  Topical cyclosporin A in nickel contact hypersensitivity: results of a preliminary clinical and immunohistochemical investigation.

Authors:  R D Aldridge; H F Sewell; G King; A W Thomson
Journal:  Clin Exp Immunol       Date:  1986-12       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.